
    
      This study is an early, open, single-centered trial. The major aim of this study is to
      evaluate the safety and tolerance of GC019F CAR-T cell immunotherapy in relapsed or
      refractory B-ALL. The study will include 6-12 subjects to receive GC019F single infusion.
    
  